The Swiss biopharmaceutical company’s shares surged in after-hours trading after it said the FDA approved its Optune Pax ...

HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, has received orphan drug designation (ODD) from the FDA for the ...

AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control ...

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this ...

A lung cancer trial bolsters a long-held idea that treatment timing matters, showing a simple shift could help immunotherapy ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

An experimental drug combination was able to effectively treat pancreatic cancer in mouse models without tumor resistance.

Researchers recently tried an experiment: Gather people who had the same kind of lung cancer and put them on the same type of treatments to fire up their immune systems. The only difference was that ...

A feature of pancreatic cancer cells' surroundings determines whether they grow fast or become resistant to chemotherapy, a ...

A cohort study examines whether the use of common medications was associated with worse outcomes in patients with lung cancer taking immunotherapy.

Finge medical groups once touted ivermectin as an effective COVID-19 treatment. But studies did not find that to be true, and there's no new evidence to suggest it can fight cancer, either.

The same drug that sparked massive controversy during Covid is now being studied as a potential cancer treatment. The National Institutes of Health has launched new preclinical research into ...